Linear Clinical Research provides early-phase and first-in-human clinical trial services to the global pharmaceutical and biotechnology industries. Since its founding in 2010, the company has secured over 170 contracts in 19 therapeutic areas, which have been part of international medical discoveries.
Linear is the only organisation in Western Australia that is dedicated to early phase clinical trial execution, and one of only four such organisations in Australia. Linear has continued to enhance its reputation as a quality driven, high touch, cost competitive organisation with access to a range of patient populations.
Linear’s advantage encompasses its multi-disciplinary teams, 40-bed clinic facilities and a volunteer database of over 14 000 contacts. Coupled with Australia’s favourable TGA regulations and tax system, Linear has been successful in attracting over 100 sponsors from 15 countries.
In 2016–17, Linear achieved 13 per cent increase in export revenue from the previous year. While the US continues to be the company’s largest export market, China was Linear’s most successful growth market for the second year in a row, achieving a 38 per cent year-on-year increase in Chinese export revenue. Of contracts awarded in 2016
Linear saw 65% from repeat or referral clients, an output of the quality service to the global biotech industry that Linear provides.
Judges noted Linear’s impressive growth in US projects and ability to leverages advantages in the domestic market to underpin its export success.